P2-278: Studies on relationship of objective response by chemotherapy and senescence induced in vitro for non small cells lung cancer  by Wang, Youzhou et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS682
P2-276 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
Efficacy of adjuvant or neoadjuvant chemotherapy with surgical 
resection of stage lB-llB Non-small-cell lung cancer
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Background: The therapeutic efﬁcacy of adjuvant or neoadjuvant 
chemotherapy with surgical resection of stage lB-llB non-small-cell 
lung cancer (NSCLC) has been less clear. We performed a retrospec-
tive study of adjuvant or neoadjuvant chemotherapy with vinorelbine 
plus cisplatin or etoposide plus cisplatin to validate the efﬁcacy on the 
patients with early stage NSCLC. Response, survival data and the feasi-
bility of chemotherapy were analyzed. 
Methods: 48 patients diagnosed as stage IB - IIB NSCLC from Janu-
ary 1994 to February 2006, were enrolled for analysis. All patients re-
ceived either 30 mg/m2 vinorelbine plus 100 mg/m2 cisplatin (n=17) or 
100 mg/m2 etoposide plus 100 mg/m2 cisplatin (n=31) every 3 weeks, 
before operation or after operation. In neoadjuvant setting, after 3 
cycles of chemotherapy, restaging was done with chest CT, followed by 
surgery. Postoperative radiotherapy was at the investigator’s discretion. 
Results: 10 patients (20.8%) had stage lB disease and 38 patients 
(79.2%) had stage llB disease. The adjuvant chemotherapy group 
was 22(45.8%) patients and neoadjuvant chemotherapy group was 26 
(54.2%) patients. The median duration of follow-up was 45.5 (6-187) 
months. The median survival was 46 (6-187) months and disease-free 
survival was 31 (5-187)months. The overall survival of patients who 
adjuvant chemotherapy was similar compared with the patients who 
neoadjuvant chemotherapy (46 vs 46 months, p=0.125). The overall 
survival of patients of stage lB patients was more prolonged than that 
of stage llB patients (51 vs 46 months, p=0.048). The Grade 3/4 he-
matologic toxicities of chemotherapy were neutropenia (n=9), anemia 
(n=1), and thrombocytopenia (n=1). 
Conclusion: The adjuvant or neoadjuvant choemotherapy of vinorel-
bine plus cisplatin or etoposide plus cisplatin has an acceptable level 
of toxicity and may prolong overall survival among patients with 
completely resected stage lB-llB NSCLC.
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Weekly Low-dose Docetaxel for Pretreated Elderly or Less Fit 
Patients with Non-small Cell Lung Cancer
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Background: Second-line single-agent docetaxel showed superiority in 
overall survival compared with best supportive care alone in previously 
treated patients with non-small cell lung cancer (NSCLC). However, 
for elderly or less ﬁt patients, chemotherapy is associated with greater 
toxicity and less beneﬁt, and the efﬁcacy of salvage docetaxel chemo-
therapy for these patients is still controversial. Therefore, we evaluated 
the efﬁcacy and toxicity proﬁles of weekly low-dose docetaxel regimen 
administered in daily clinical practice for elderly or less ﬁt NSCLC 
patients previously exposed to chemotherapy. 
Methods: Between May 2004 and January 2007, forty unselected, 
consecutive and prospectively enrolled patients with stage IIIB or IV 
NSCLC, previously treated with one or more chemotherapy regimens, 
received docetaxel as single-agent salvage chemotherapy at Seoul Na-
tional University Bundang Hospital. All patients were aged ≥ 65 years, 
or had an ECOG performance status of ≥ grade 2 in the cases of ages < 
65 years. Docetaxel was administered at a dose of 25 mg/m2 weekly on 
days 1, 8, and 15 of a 28-day cycle in an outpatient setting. 
Results: Median age was 66 years (range 38 to 80). Twenty-nine 
patients (73%) received docetaxel as second-line chemotherapy and 
eleven (28%) as third- or fourth-line treatments. Platinum, gemcitabine, 
paclitaxel, epidermal growth factor (EGFR) inhibitors were previously 
employed in 39 (98%), 37 (93%), 9 (23%) and 9 patients (23%), re-
spectively. A median of 2 cycles (range 1 to 6) were administered and, 
of 40 patients enrolled, nine patients (23%) showed partial responses. 
Nine patients (23%) showed stable disease and 17 (43%) progressive 
disease. Five patients (13%) were not evaluable. Grade 3/4 toxicities 
were rare: asthenia in 8% of patients, anorexia in 8%, mucositis in 5%, 
diarrhea in 3%, neutropenia in 3%, nail change in 3%, and peripheral 
neuropathy in 3%. Drug toxicity was the reason for the treatment 
discontinuation in 5 patients (13%). At median follow-up of 18 weeks, 
22 patients are alive. Median progression-free survival and overall sur-
vival were 9.9 weeks (95% conﬁdence interval [CI]: 7.1~12.7 weeks) 
and 37.7 weeks (95% CI: 21.0~54.3 weeks), respectively.
Conclusions: Weekly low-dose docetaxel appears to be well toler-
ated as salvage chemotherapy for previously treated elderly or less ﬁt 
patients with NSCLC. The efﬁcacy of this low-dose regimen seems to 
be comparable to the standard 3-week or higher-dose weekly docetaxel 
regimens. This approach provides a reasonable alternative for pretreat-
ed elderly or less ﬁt patients with NSCLC. 
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Background: Lung cancer is the most common cause of cancer death 
throughout the world. Chemotherapy is a main treatment modality but 
resistance to treat is a major problem in non-small cell lung cancer 
(NSCLC). Neoplastic transformation involves events that inhibit the 
program of senescence, and tumor cells were believed until recently to 
have lost the ability to senesce. As chemotherapeutic drugs can induce 
tumor cells to senesce, the aim of the present study was to investigate 
correlation between the clinical response of taxanes plus cisplatin 
combination chemotherapy and combination of docetaxel and cisplatin 
(DC) induced senescence in vitro, the contribution of m-P53 protein re-
leasing in tumor cells, and whether DC induced senescence assay could 
have clinical implications as a chemsensitivity indicator in vivo.
Methods: Sixty-seven specimen obtained from NSCLC patients from 
Jan 1, 2003 to Jun 30, 2006. The patients consisted of 48 males and 
19 females, ranging in age from 54 to 82 years (mean, 67.5 years), 41 
cases were diagnosed as pathological stage IIIb, 26 cases were diag-
nosed as stage IV. Thirty-nine tumors were conﬁrmed to be adenocarci-
nomas, 28 were conﬁrmed to be squamous cell carcinomas. All patients 
accept 2-6 cycles combination chemotherapy of Taxanes (docetaxel 
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40 mg/m2, d1;d8, or paclitaxel 175mg/m2, d1) plus cisplatin (CDDP, 
25mg/m2, d2-4). Patients were divided into chemoresponsive (CR+PR) 
and chemoresistant (SD+PD) groups according to objective response 
status which was evaluated by RECIST system. Tumor cells from 
specimens of bronchoscopic, surgical biopsy and pleural effusion cell 
collection had been cultured and treated with DC in vitro. The m-P53of 
culture supernatant was measured by ABC-ELISA kit before DC treat-
ment. The telomerase activity was determined by the telomeric repeat 
ampliﬁcation protocol (TRAP) based PCR-ELISA kit and apoptosis 
was determined by TdT-mediated d-UTP-X nick-end labeling (TU-
NEL) Assay. Data represent as both actual detected and positive value. 
The senescence of tumor cells deﬁned as that, apoptosis rate increased 
more than 50% to control, and telomerase activity decreased less than 
50% to control. 
Results: There was no signiﬁcant deference between clinical treatment 
response and sex, pathological type, specimen origin, or m-P53 status 
in cultured cell supernatant. Telomerase activity and apoptosis rate was 
positive in 61.1% (41/67) and 25.4% (17/67) of all samples respec-
tively. A signiﬁcant difference of senescence of tumor cells treated by 
DC, was existed between chemoresponsive and chemoresistant patients 
groups (P<0.05). Multinomial logistic regression analyses shown that 
telomerase activity decreased less than 50% in vitro may be an indica-
tor of clinical response for taxanes plus cisplatin chemotherapy. Odds 
ratio is 4.226, p<0.05. 
Conclusion: For NSCLC, chemotherapy induced lung cancer tu-
mor cells senesce in vitro may be a promising predicator for clinical 
response. The relationship between clinical response and detectable 
m-P53 in vitro still is obscure.
P2-279 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
Outcome of advanced nonsmall cell lung cancer patients receiving 
gemcitabine and weekly paclitaxel as first-line treatment
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Background: Gemcitabine and paclitaxel were both active for ad-
vanced nonsmall cell lung cancer (NSCLC) patients. Combinations 
of gemcitabine and paclitaxel with various doses and schedules were 
shown to be effective treatment for these patients. The survival out-
come of these patients are not clear.
Methods: Patients with advanced NSCLC in a phase II study of 
weekly paclitaxel and gemcitabine as ﬁrst-line treatment were followed 
until their death. Second or further lines of treatment were recorded. 
Results: Thirty-seven patients were accrued receiving a total of 188 
cycles of gemcitabine and paclitaxel treatment. Toxicities were mild. 
Twenty-three patients had partial response (overall response rate, 62%; 
95% conﬁdence interval, 46-78%). Median time to treatment failure 
was 6.0 months. Twenty-seven (73%) patients received second-line 
anticancer drug treatment. Twenty-three (62%) patients were able to 
receive platinum doublet. Median survival after second-line treat-
ment was 10.9 months. Median, 1- and 2-year survival of 37 patients 
were16.8 months, 59% and 27%. There was a statistically signiﬁcant 
difference in median survival between patients who can or cannot 
receive second-line treatment (21.9 vs. 3.1 months, p < 0.00001). 
Conclusions: Weekly paclitaxel with gemcitabine is effective and well 
tolerated as ﬁrst-line treatment for advanced NSCLC patients. Long 
survival may be due to platinum doublet second-line chemotherapy.
P2-280 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
Gemcitabine and Oxaliplatin as second and third line therapy of 
advanced and metastatic non-small cell lung cancer (NSCLC): 
evidence of clinical activity and improvement in quality of life.
Lopes, Gilberto1 Alencar, Alvaro2 Blaya, Marcelo2 Raez, Luis2 Farfan, 
Nancy2 Walker, Gail2 Flores, Aurea2 Macyntire, Jessica2 Rocha Lima, 
Caio2 
1 Johns Hopkins Singapore International Medical Center, Johns Hop-
kins University, Singapore, 2 Sylvester Cancer Center, University of 
Miami, Miami, FL, USA 
Background: Gemcitabine is active as second line therapy in NSCLC. 
Oxaliplatin may be non-cross resistant with other platinum agents used 
as ﬁrst-line therapy in NSCLC. The combination of gemcitabine and 
oxaliplatin (GEMOX) is synergistic in pre-clinical models and clinical 
trials have shown that it is safe and efﬁcacious in several tumor types, 
including NSCLC.
Methods: A phase II trial was designed to assess the efﬁcacy and 
tolerability of gemcitabine 1,000 mg/m2 over 100 min in combination 
with oxaliplatin 100 mg/m2 over 2 hours both given on days 1 and 
15 of a 28-day cycle. Patients with NSCLC were eligible if they had 
progressed after ﬁrst line treatment. Primary endpoint was objective 
response rate assessed by RECIST. Planned sample size is 30 patients 
over a period of 2 ½ years. Functional Assessment of Cancer Therapy-
Lung (FACT-L) v.4 questionnaire was used to assess the quality of life 
of patients on therapy.
Results: Twenty-two patients have been enrolled. 13 were men (59%) 
and 9 were women (41%). Fifteen patients were Hispanic (68%), four 
were Caucasian (18%), and 3 were African-American (13%). Median 
age was 55 years. Histologic subtypes were as follows: adenocarcino-
ma, 12; NSCLC not otherwise speciﬁed, 7; squamous cell carcinoma, 
3. Nine patients had an ECOG performance status (PS) of 0 (41%) and 
13 had a PS of 1 (59%). Two patients were never smokers. A total of 
56 cycles have been administered (median 2, range 1 to 6). GEMOX 
was given as second-line therapy to 18 patients (81%), and as third-line 
to 4 patients (18%). Twenty patients are available for assessment of 
response. Two patients had a conﬁrmed partial response (10%) and an-
other eight had stable disease (40%). Two patients died on study from 
disease progression leading to respiratory and multi-organ failure. The 
following Grade 3 and 4 adverse events were seen in 2 patients each: 
fatigue, dyspnea, anemia, and multi-organ failure. Preliminary results 
of FACT-L analysis in 19 pts show improvement in Lung Cancer Sub-
scale (LCS) score in 25% of the patients after 2 cycles of therapy.
Conclusions: Gemcitabine in combination with oxaliplatin is active 
and well tolerated as second and third line treatment for advanced 
NSCLC. Improvement of LCS score after 2 cycles suggests a clinical 
beneﬁt that is beyond the observed response rate of 10%.
